Biotech

All Articles

AstraZeneca blog posts information on internal opponents to AbbVie, Pfizer ADCs

.AstraZeneca has shared a very early check out the efficiency of its internal antibody-drug conjugat...

iTeos- GSK's TIGIT celebrity shows relevant improvement

.After introducing a phase 3 launch based on positive midstage end results, iTeos and also GSK are a...

More collaborative FDA can increase rare disease R&ampD: report

.The FDA should be more available as well as collective to let loose a surge in commendations of unu...

Zenas, MBX, Bicara scalp to Nasdaq in scorching time for biotech IPOs

.It's an uncommonly occupied Friday for biotech IPOs, along with Zenas BioPharma, MBX as well as Bic...

Atea's COVID antiviral fails to halt hospital stays in period 3

.Atea Pharmaceuticals' antiviral has actually stopped working another COVID-19 test, however the bio...

Neurocrine's bid to spare schizophrenia prospect stops working

.Neurocrine Biosciences' mental illness plan pivot has stopped working. The biotech was actually una...

Sanofi spends $110M upfront for late-stage radioligand therapy

.Sanofi has actually created an overdue entrance to the radioligand party, paying for 100 million eu...

F 2G rears $100M for 2nd try to acquire brand-new antifungal to market

.After F2G's first try to receive a brand-new course of antifungal to market was actually derailed b...

Moderna targets $1.1 B in R&ampD investing slices, drops 5 programs amidst earnings stress

.Moderna has pledged to reduce R&ampD costs through $1.1 billion by 2027. The selection to retract t...

Sanofi's $80M bet on Pivot dystrophy medication ends in stage 3 lose big

.Simply 4 months after Sanofi bet $80 million in beforehand money on Pivot Rehabs' losmapimod, the p...